logo
    • English
      • 简体中文
      • 繁體中文
  • Home
  • Articles
    • Insights
    • Client Press Releases
    • Client Coverage
  • Interviews
    • CEO Interview
    • PDAC Interview
  • Clients
    • Featured Companies
    • In-depth Analysis
  • Markets
    • Stock Tracker
    • Markets at a glance
    • Investing 101
      • Investing in Mining 101
        • Gold and Precious Metals
        • Electric and Battery Metals
        • Base Metals
        • Other Mining Subsectors
  • METALS 100
  • GCFF Event
    • Next Event
    • Past Events
  • Home
  • Trends & Strategies
  • Life Science & Technology Weekly 156 – Magnolia Neurosciences Launches with $31 Million

Life Science & Technology Weekly 156 – Magnolia Neurosciences Launches with $31 Million

Published on: Aug 16, 2018
Author: Editor
  • Share article:

Check www.nai500.com for more investment opportunities

Click here to find more details

Suggested Opportunity

Tenet Fintech Group Inc.

Tenet Fintech Group Inc. (CSE: PKK, OTC Pink: PKKFF)

Commercial Lending in China Ready to Tenet!

This is NAI’s new Life Science and Technology Weekly. We will be covering the latest news in life science, pharmaceutical, biotech and technology sectors every week. To continue to receive NAI’s Life Science and Technology Weekly, please click Here to subscribe.

Biotechnology Life Science Technology

Related Posts

Alphabet股价续涨,但反垄断阴霾仍存

Market Enthusiastic About SpaceX, but Alphabet and TSMC Offer Better Opportunities

如何通过一只ETF投资整个生物技术行业?

Investors Face a Dilemma,Two Energy ETFs Each Have Their Own Advantages

豪掷50亿!揭秘礼来继减肥针后的下一个增长引擎

Strong Demand for GLP-1 Drugs Drives Eli Lilly’s Leadership with New Oral Medication and Acquisitions

悲观情绪蔓延时,高盛看好私募信贷三巨头

AI Enters Global Credit Market, Data Security Emerges as Biggest Concern

涨幅超英伟达14倍,这只小型人工智能股仍在上涨

Broadcom’s Weak Guidance Triggers Chip Stock Turmoil, But Wall Street Says “This Is a Perfect Buying Opportunity”

Two Beaten-Down Pharma Giants: Biotech’s Cyclical Turn Delivers Prime Dip-Buy Opportunities

Two Beaten-Down Pharma Giants: Biotech’s Cyclical Turn Delivers Prime Dip-Buy Opportunities

Related News

Market Enthusiastic About SpaceX, but Alphabet and TSMC Offer Better Opportunities

17 hours ago.

Strong Demand for GLP-1 Drugs Drives Eli Lilly’s Leadership with New Oral Medication and Acquisitions

21 hours ago.

Targeting Pre-IPO Investment Demand for Unicorns, Coinbase Launches SpaceX Perpetual Futures Contract

21 hours ago.

AI Enters Global Credit Market, Data Security Emerges as Biggest Concern

22 hours ago.

Top Stories

Vanguard’s VOO Becomes World’s First $1 Trillion ETF, Marking Passive Investing’s Historic Ascent
Financial Service

Vanguard’s VOO Becomes World’s First $1 Trillion ETF, Marking Passive Investing’s Historic Ascent

Alphabet’s Growth Thesis Reshaped by Anthropic’s Looming IPO via TPU Supply and Equity Stakes
Technology

Alphabet’s Growth Thesis Reshaped by Anthropic’s Looming IPO via TPU Supply and Equity Stakes

We connect Investors to Opportunities.

Financial Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

 
QuoteMedia logo

Head Office

  • 2209 – 1111 Alberni Street
    Vancouver, BC Canada V6E 4V2
  • Phone: (604) 488-8878
  • Fax: (604) 488-0868
  • Toll Free: 1 (866) 833-5517
  • Email: [email protected]

Shanghai Office

  • 06 - 607, 6/f. No.800 Shangcheng
    Road Pudong New District Shanghai,
    China
  • Phone: 021-68883919
  • Fax: 021-68882879
  • Email: [email protected]

Important Links

  • Privacy Policy
  • Terms of Use
  • Content Partner
  • NAI500 Investor Relations Services
  • About Us
  • Contact Us

© 2026 NAI Interactive Ltd. All Rights Reserved

gcff

logo

Website Design Vancouver by Nirvana Canada